Filing Details
- Accession Number:
- 0001209191-20-048868
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-09-01 08:17:31
- Reporting Period:
- 2020-08-28
- Accepted Time:
- 2020-09-01 08:17:31
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1717452 | Odonate Therapeutics Inc. | ODT | () | 4 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1178579 | C Kevin Tang | 4747 Executive Drive Suite 210 San Diego CA 92121 | Chief Executive Officer | Yes | Yes | Yes | No |
1191935 | Tang Capital Partners Lp | 4747 Executive Drive Suite 210 San Diego CA 92121 | No | No | Yes | No | |
1232621 | Tang Capital Management Llc | 4747 Executive Drive Suite 210 San Diego CA 92121 | No | No | Yes | No | |
1495904 | G John Lemkey | 4747 Executive Drive Suite 210 San Diego CA 92121 | Chief Operating Officer | No | Yes | No | No |
1759910 | S Michael Hearne | 4747 Executive Drive Suite 210 San Diego CA 92121 | Chief Financial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2020-08-28 | 1,052,631 | $14.25 | 15,127,900 | No | 4 | P | Indirect | By LP |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Indirect | By LP |
Footnotes
- The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management,LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares ofcommon stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authorityto vote such shares. John Lemkey is the Chief Operating Officer of Odonate Therapeutics, Inc., as well as Chief Operating Officer of TCM. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang, Mr. Lemkey and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP.